Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients.

Sood S, Yu L, Visvanathan K, Angus PW, Gow PJ, Testro AG.

World J Hepatol. 2016 Dec 18;8(35):1569-1575. doi: 10.4254/wjh.v8.i35.1569.

2.

Coagulation in acutely ill patients with severe chronic liver disease: Insights from thromboelastography.

Lloyd-Donald P, Vasudevan A, Angus P, Gow P, Mårtensson J, Glassford N, Eastwood GM, Hart GK, Bellomo R.

J Crit Care. 2016 Nov 4;38:215-224. doi: 10.1016/j.jcrc.2016.10.030. [Epub ahead of print]

PMID:
27978499
3.

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.

Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P.

Liver Int. 2016 Nov 29. doi: 10.1111/liv.13331. [Epub ahead of print]

PMID:
27896895
4.

Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score.

Sinclair M, Gow PJ, Grossmann M, Shannon A, Hoermann R, Angus PW.

Liver Transpl. 2016 Nov;22(11):1482-1490. doi: 10.1002/lt.24607.

PMID:
27542090
5.

Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.

Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ.

J Hepatol. 2016 Nov;65(5):906-913. doi: 10.1016/j.jhep.2016.06.007.

PMID:
27312945
6.

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.

Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, Rivera LR, Furness JB, Forbes JM, Angus PW.

World J Gastroenterol. 2016 Sep 21;22(35):8026-40. doi: 10.3748/wjg.v22.i35.8026.

7.

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.

McElroy HJ, Roberts SK, Thompson AJ, Angus PW, McKenna SJ, Warren E, Musgrave S.

J Med Econ. 2017 Jan;20(1):72-81.

PMID:
27552282
8.

Outpatient Terlipressin Infusion for the Treatment of Refractory Ascites.

Gow PJ, Ardalan ZS, Vasudevan A, Testro AG, Ye B, Angus PW.

Am J Gastroenterol. 2016 Jul;111(7):1041-2. doi: 10.1038/ajg.2016.168. No abstract available.

PMID:
27356836
9.

The role of the gut microbiota in NAFLD.

Leung C, Rivera L, Furness JB, Angus PW.

Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. doi: 10.1038/nrgastro.2016.85. Review.

PMID:
27273168
10.

Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.

Betz-Stablein BD, Töpfer A, Littlejohn M, Yuen L, Colledge D, Sozzi V, Angus P, Thompson A, Revill P, Beerenwinkel N, Warner N, Luciani F.

J Virol. 2016 Jul 27;90(16):7171-83. doi: 10.1128/JVI.00243-16.

PMID:
27252524
11.

Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.

Lim EJ, Chin R, Nachbur U, Silke J, Jia Z, Angus PW, Torresi J.

J Viral Hepat. 2016 Sep;23(9):730-43. doi: 10.1111/jvh.12541.

PMID:
27167351
12.

Liver Failure Complicating a Febrile Illness in a Middle-Aged Man.

Vasudevan A, Ardalan Z, Angus P.

Gastroenterology. 2016 Jun;150(7):1542-4. doi: 10.1053/j.gastro.2016.01.044. No abstract available.

PMID:
27151259
13.

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.

Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Böcher W, Mensa FJ.

Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649.

PMID:
27140229
14.

High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease.

Sinclair M, Gow PJ, Angus PW, Hoermann R, Handelsman DJ, Wittert G, Martin S, Grossmann M.

Liver Int. 2016 Nov;36(11):1619-1627. doi: 10.1111/liv.13122.

PMID:
26998685
15.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X; SOLAR-2 investigators..

Lancet Infect Dis. 2016 Jun;16(6):685-97. doi: 10.1016/S1473-3099(16)00052-9.

PMID:
26907736
16.

Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions.

Sinclair M, Gow PJ, Grossmann M, Angus PW.

Aliment Pharmacol Ther. 2016 Apr;43(7):765-77. doi: 10.1111/apt.13549. Review.

PMID:
26847265
17.

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ.

Hepatology. 2016 May;63(5):1430-41. doi: 10.1002/hep.28473.

18.

Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?

Elliott TR, Symes T, Kannourakis G, Angus P.

BMJ Case Rep. 2016 Jan 6;2016. pii: bcr2015213189. doi: 10.1136/bcr-2015-213189.

PMID:
26740270
19.

Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant.

Adams LA, Arauz O, Angus PW, Sinclair M, MacDonald GA, Chelvaratnam U, Wigg AJ, Yeap S, Shackel N, Lin L, Raftopoulos S, McCaughan GW, Jeffrey GP; Australian New Zealand Liver Transplant Study Group..

J Gastroenterol Hepatol. 2016 May;31(5):1016-24. doi: 10.1111/jgh.13240.

PMID:
26589875
20.

Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.

Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H.

Scand J Clin Lab Invest. 2016;76(1):64-73. doi: 10.3109/00365513.2015.1099722.

PMID:
26549495
Items per page

Supplemental Content

Support Center